Compare iShares China Large-Cap ETF (FXI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Sanofi SA — how do they compare? iShares China Large-Cap ETF trades at $34.25 (market cap $3.86B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 24.7× iShares China Large-Cap ETF's market cap, and Sanofi SA pays a 6.01% dividend while iShares China Large-Cap ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 150 Days and Sanofi SA for 94 Days on average.
| FXI | SNY | |
|---|---|---|
Market Cap | $3.86B | $95.18B |
Volume | 16,323,837 | 2,995,646 |
52-Week High | $41.08 | $52.34 |
52-Week Low | $31.59 | $39.51 |
Typical Hold Time | 150 Days | 94 Days |
Sector | — | Health |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $33.45 with minimal daily movement (+0.09%), reflecting subdued momentum amid bearish technical signals. The ETF faces significant technical headwinds with 17 sell signals versus 1 buy, though oscillators remain neutral. Recent news highlights China's mixed economic signals, including strong export growth but persistent overcapacity concerns. The Trump-Xi summit in September 2026 offered limited progress on trade tensions, maintaining geopolitical uncertainty for Chinese equities.
FXI presents a value opportunity with a P/E ratio of 11.10—half the S&P 500's valuation—and a 1.98% yield, but faces substantial risks from China's economic rebalancing, weak domestic consumption, and potential export controls. Investor sentiment is cautious due to political and macroeconomic headwinds, though some analysts see long-term potential if China stabilizes growth.
Sanofi (SNY) trades at $40.23, showing minimal daily movement with a 0.07% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental performance, including three consecutive quarterly earnings beats. Recent expansion of the immunology alliance with Regeneron through an $8 billion deal highlights strategic growth initiatives. Valuation metrics show a P/E of 22.14 and P/S of 1.77, while profitability remains solid with a 72.77% gross margin.
SNY offers steady growth potential driven by pipeline expansion and Dupixent momentum, though patent expiration risks loom. Analyst sentiment is cautiously optimistic with 44% buy ratings, but technical weakness and projected 2026 earnings decline present near-term headwinds. The stock represents a balanced opportunity for long-term investors seeking pharmaceutical exposure with manageable risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
